

Metal complexes of flavonoids: their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities

Article

Accepted Version

Khater, M., Ravishankar, D., Greco, F. and Osborn, H. (2019) Metal complexes of flavonoids: their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities. Future Medicinal Chemistry, 11 (21). ISSN 1756-8927 doi: https://doi.org/10.4155/fmc-2019-0237 Available at http://centaur.reading.ac.uk/86372/

It is advisable to refer to the publisher's version if you intend to cite from the work. See <u>Guidance on citing</u>.

To link to this article DOI: http://dx.doi.org/10.4155/fmc-2019-0237

Publisher: Future Science Group

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in



the End User Agreement.

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Metal complexes of Flavonoids: Their synthesis, characterization, and enhanced anti-oxidant and anti-cancer activities

3

4 Mai Khater^{1,2}, Divyashree Ravishankar¹, Francesca Greco¹ and Helen M.I. Osborn¹*

⁵ ¹ School of Pharmacy, University of Reading, Whiteknights, Reading, RG6 6AD. UK

⁶ ² Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Division,

7 National Research Centre, Cairo, Egypt.

8

9 Abstract

Flavonoids are polyphenolic compounds of natural origin. They are extensively studied within 10 11 drug discovery programmes due to their wide ranging biological activities such as anti-microbial, anti-oxidant, anti-tumor, neuroprotective and cardioprotective properties. The ability of 12 flavonoids to coordinate with metal atoms has provided new leads for drug discovery 13 programmes, with better pharmacological activities and clinical profiles than the parent 14 flavonoids. In this review, the enhanced anti-oxidant and anti-cancer activities of flavonoid metal 15 complexes versus the parent flavonoids are discussed. Possible mechanisms of action for the 16 metal complexes, such as DNA binding and apoptosis induction, are also presented alongside an 17 18 overview of the synthesis of the metal complexes, and the different techniques used for their characterization. 19

20 Keywords

21 Flavonoid, metal, flavonoid metal complex, anti-oxidant, anti-cancer.

22 Introduction

23 Flavonoids are phytochemicals that are mainly found in tea, citrus fruit, berries, apples and


legumes. Chemically, they are polyphenolic compounds with a C_6 - C_3 - C_6 ring system (Figure 1)

and they are often found in esterified or glycosylated forms [1]. It was not until the 1990's that


26 research on flavonoids witnessed significant progress, with the number of publications increasing

by approximately 6-fold, from 524 in 1990 to 3147 in 2017. As a result it is now well established

- that flavonoids have a wide and diverse range of biological activities [2, 3] such as anti-viral [4-
- 6], anti-bacterial [7-10], neuroprotective [11-13], cardioprotective [14, 15], anti-oxidant [16-18]
- and anti-cancer [3, 19, 20] properties.



Basic skeleton of flavonoids







Figure 1. Chemical structures of flavonoids from which organometallic derivatives have been
 prepared

With respect to the beneficial health effects of flavonoids, the greatest impact has been seen 37 38 within the anti-cancer field [2]. Flavonoids are known to interfere with an array of targets affecting cancer growth and progression. For example, they have been shown to induce cell cycle 39 40 arrest and apoptosis [21] in addition to inhibiting mitotic spindle formation [22] and angiogenesis [23, 24]. Despite the advantages of having a compound that can interact with 41 different targets, this can be a limitation due to limited selectivity. Indeed, this has been one of 42 the biggest obstacles in the use of flavonoids as potential drugs due to its direct relation with 43 44 adverse effects and poor *in vivo* toxicity profiles. However, despite the extensive research and number of structures and the activity reported for them, no flavonoid has to date reached the 45

market and only a limited number are in clinical investigation as anti-cancer agents, eg 46 flavopiridol (phase-II) [25, 26], silibinin (phase-II) [27, 28], quercetin (phase-II) [29, 30] and the 47 quercetin derivative QC12 (phase-I) [31] (Figure 2). Arguably, the main drug development 48 challenge is the poor bioavailability of flavonoids, resulting from water insolubility and 49 susceptibility to glucourinidation and/or methylation by intestinal and liver metabolism (first 50 pass effect). There are several studies on the pharmacokinetics of flavonoids indicating their poor 51 bioavailabilities. Wu et al., for instance, reported the absolute oral bioavailability of silibinin in 52 rats to be approximately 0.95% [32]. In another study, flavopiridol's mean oral bioavailability 53 following bolus intra-gavage was shown to be 20% [33]. Moreover, a study by Gugler et al. 54 failed to detect any plasma quercetin concentrations in subjects receiving 4 g orally [34]. 55



56

57


Figure 2. Flavonoids in clinical trials as anti-cancer agents

58 Due to the presence of hydroxyl and oxo groups within flavonoids, they possess metal chelating 59 abilities that can have profound effects on their pharmacokinetic and pharmacological properties 60 [35, 36]. The flavonoid structure, type of chelating metal and the pH of the surrounding medium are determining factors of the preferred coordination site [37]. Metal atoms have beneficial biological properties such as chelating free radicals and binding to DNA [38]. These properties can cause synergistic effects when combined with other active chemical entities such as the flavonoids. Accordingly, metal complexation is reported to enhance the anti-oxidant, antiproliferative and chemical properties of parent flavonoids. This review will therefore highlight important advances within the field of metal-flavonoid complexes with particular emphasis on their synthesis, methods of characterization, anti-oxidant and anti-proliferative activities.

- 68
- 69

70 Synthesis and characterization of flavonoid metal complexes

Flavonoid metal complexes are generally synthesized by dissolving a flavonoid salt in an 71 72 alcoholic or aqueous solution, followed by the addition of the metal salt also in alcoholic or aqueous solution. The reaction can be carried out under different conditions of stirring and/or 73 74 heating, normally a base is used to deprotonate the hydroxyl groups and facilitate metal 75 coordination. The complex usually precipitates from solution and is then filtered and air dried 76 (Table 1). Preparations of ferrocenyl flavonoid complexes, where the ferrocenyl moiety acts as a replacement for ring B, follow a different synthetic approach. Ferrocenyl aurones are obtained 77 via a classic Claisen-Schmidt condensation of ferrocene carboxaldehyde and various 2-78 79 hydroxyacetophenones to obtain the corresponding ferrocene chalcones [39, 40]. The synthesized chalcones are then treated with mercury acetate in pyridine to form the ferrocenyl 80 aurones that can be isomerized into their flavone counterparts by heating in ethanol at reflux with 81 potassium cyanide (Figure 3) [39, 40]. 82




83 84

85


Ferrocenyl Chalcones

Ferrocenyl Aurones

Ferrocenyl Flavones



Heck cross-coupling reaction of vinyl ferrocene with 6-bromochromones (Figure 4) [41].



89


86

90

Figure 4. Synthesis of ferrocenyl flavonoids using Pd

Structural characterization of metal complexes can be achieved using a number of methods 91 92 (Table 1). Fourier transform infra-red (FT-IR) spectroscopy can indicate the coordination site of the metal. Complexation of the metal atom with the C=O group, for instance, causes an increase 93 94 in the bond length which is manifested as a decrease in the frequency of the C=O peak. Coordination with OH groups leads to disappearance of their characteristic broad peaks v OH at 95 96 3600-3200 cm⁻¹. However, this disappearance can be masked by the presence of other OH groups in the flavonoid structure and in the H₂O molecules incorporated in the metal sphere 97 during complexation. Therefore, IR spectroscopy is not a helpful tool in determining which OH 98 groups are specifically coordinated to the metal atom. ¹H NMR spectroscopic analysis can 99 100 provide a better alternative where the disappearance of an OH peak from the ¹H NMR spectrum corresponds to coordination at this particular OH group. For example, the disappearance of the 5-101 OH peak at δ 10.52 ppm of the **lanthanum-18** complex proved coordination at this OH in ring 102 A [42]. Heteroatom NMR spectroscopic analysis is also extremely useful. For example, 103 104 Tabassum et al. used ¹¹⁹Sn NMR spectroscopic analysis to prove the presence of stannous atoms in the synthesized bi-metallic complexes **31** and **32** (Figure 6) [43]. ¹⁹⁵Pt NMR spectroscopic 105 analysis was also used to prove the structure of complex 68 [44]. Electron Paramagnetic 106 107 Resonance (EPR) spectroscopy is also a helpful technique which is similar to NMR spectroscopy 108 but more sensitive as it explores the interaction between an external magnetic field and unpaired 109 electrons rather than nuclei. This is attributed to the fact that the amount of energy absorbed by a spinning electron is higher than that absorbed by a nucleus. This technique is more difficult to 110 use as it requires background knowledge of subjects like quantum mechanics and mathematical 111 techniques [45]. However it was used by Tabassum and Naso et al. groups to elucidate structures 112

of complexes (**31** and **32**) and (**33**, **37**, **VOhespiridin**, **VOsilibinin** and **VOmorin**), respectively
[43, 46-49].



115

116

Figure 5. UV absorption bands using quercetin as an illustrative example

Flavonoids display absorption bands in the UV-Vis region due to electronic $\pi - \pi^*$ transitions 117 [50, 51]. These transitions are responsible for the two characteristic benzoyl and cinnamoyl 118 bands of flavonoids at 240-280 nm and 320-385 nm, respectively (Figure 5) which are 119 bathochromically shifted after chelating with metals [52]. The observation of a red shift in one 120 band rather than the other verifies chelation with that particular ring [53-55]. Although the shift 121 is small in many cases, it gives a good insight when overlapped with the parent's spectrum. UV-122 Vis absorption bands are also characteristic to binding in other sites. Analysis of the spectra of 123 **VOhespiridin** showed complexation with the rutinose sugar part [46]. Its electronic spectra 124 showed bands at 358, 520 and 702 nm in agreement with the three band pattern at ca. 420, 500 125 126 and 700 nm observed for similar sugar vanadyl(IV) complexes coordinated through deprotonated 127 cis-hydroxyl groups [56]. UV-Vis spectra can also help in detecting the stoichiometry of the complex. This is achieved by monitoring the absorption intensity of the ligand through a range of 128 concentrations until the reaction is completed [46, 47, 57, 58]. Different methods can then be 129 130 used to represent the data, e.g. Job's method, from which ligand-metal ratio can be interpreted. 131 Similarly, fluorescence of free parents can be compared to their complexes at a specific wavelength. Peaks from complexes are higher in intensity and are shifted to lower wavelengths 132 ca. 15-20 nm [55]. Elemental analysis and mass spectrometry provide complementary 133

134 information about the molecular formulae of the resulting complexes. In a recent study by Wang et al. the elemental analysis of a lead-luteolin complex was determined by scanning electron 135 microscope (SEM) equipped with energy dispersive spectroscopy (EDS) [59]. The experimental 136 values of weight and atomic number percentages of carbon, oxygen and lead atoms favored a 2:1 137 rather than 1:1 complex [59]. Analysis of the fragmentation pattern in mass spectrometry 138 specifies how many metal atoms are coordinated in the complex [43, 60-64]. Roy et al. and Naso 139 et al. reported the synthesis of two different complexes (36 and 37 respectively) using the same 140 ligand (Luteolin) and metal (Vanadium) [49, 65]. The two complexes are reported to differ in 141 their stoichiometries and metal coordination sites which may have resulted from different 142 ligand/metal ratios added during the synthesis process. Thus for complex 36, two luteolin 143 molecules are reported to chelate to the oxidovanadium(VI) group via the 4-C=O and 5-OH 144 functionalities, whilst 37 is reported to contain only one luteolin chelated to the 3' and 4' cis-OH 145 groups in ring B. Among the characterization techniques provided by Roy and his group, mass 146 147 spectrometry data supported their structural hypothesis for complex 36. Thus peaks at m/z623.11, 639.89 and 658.21 represented two luteolin + one vanadium, two luteolin + vanadium 148 149 oxide and two luteolin + vanadium oxide with one molecule of water, respectively. When deducing the structure of complex 37, Nato et al. demonstrated that the FT-IR spectrum showed 150 no change in the C=O and the C2=C3 bands, in addition to an increase of 44 cm⁻¹ of the 4'-OH 151 band, indicating chelation with ring B. EPR and UV-Vis spectra of complex 37 also supported 152 153 the same findings. Thermal gravimetric studies provide information on the heat-induced decomposition of the complex as a function of temperature or time. Dehydration happens during 154 155 the early stages at temperatures ranging from 100-250 °C. This is followed by decomposition of the ligand at higher temperatures (400-600 °C). At temperatures as high as 900 °C, the complex 156 157 decomposes completely leaving the metal oxide [42, 43, 55, 60, 62, 66].

158 Nevertheless, the best proven technique to confirm a theoretical structure is X-ray 159 crystallography. Unfortunately, it is not feasible to apply this to all synthesized molecules due to 160 the specific crystal requirements needed to run an X-ray. Only structures of complexes **49**, **51**, **53** 161 and **55** [67, 68] were proven by X-ray crystallography.

162

In general, all the used characterization methods can provide helpful information of varyingimportance. NMR and UV-Vis spectroscopy are the most insightful if X-ray is not feasible.

- 165 Other methods like IR spectroscopy, elemental analysis and mass spectrometry can complement
- the results obtained and offer the advantages of being easy to interpret and available in most
- 167 research facilities.

Flavonoid Solution	Metal	Base used and pH	Final product Formula	Characterization	Ref
Quercetin.2H ₂ O in EtOH	NiCl ₂ .6H ₂ O	NaOEt 6-7	Ni(Que) ₂ (H ₂ O) ₂	UV IR Elemental Analysis	[54]
	CuCl ₂ .2H ₂ O	NaOEt 6-7	Cu(Que) ₂ (H ₂ O) ₂	UV IR Elemental Analysis	[53]
	La acetate Nd acetate Eu acetate Gd acetate Tb acetate Dy acetate Tm acetate Y acetate	NaOEt <i>N.A</i> .	La(Que) $_{3}(H_{2}O)_{6}$ Nd(Que) $_{3}(H_{2}O)_{6}$ Eu(Que) $_{3}(H_{2}O)_{6}$ Gd(Que) $_{3}(H_{2}O)_{6}$ Tb(Que) $_{3}(H_{2}O)_{6}$ Dy(Que) $_{3}(H_{2}O)_{6}$ Tm(Que) $_{3}(H_{2}O)_{6}$ Y(Que) $_{3}(H_{2}O)_{6}$	UV IR ¹ H NMR TG-DTA Fluorescence analysis Electrochemistry Elemental analysis	[55]

Table 1. Summary of synthetic conditions and characterization methods for flavonoid metal complexes

[Cu(Que)2(H2O)2] in MeOH	SnCl4	N.A.	[Cu(Que) ₂ (H ₂ O) ₆ -Sn ₂ Cl ₄]	IR ¹ H, ¹³ C & ¹¹⁹ Sn NMR EPR ESI-MS TG-DTG	[43]
[Zn(Que)2(H2O)2] in MeOH	SnCl4	N.A.	[Zn(Que) ₂ (H ₂ O) ₆ -Sn ₂ Cl ₄]	IR ¹ H, ¹³ C & ¹¹⁹ Sn NMR EPR ESI-MS TG-DTG	[43]
Chrysin in EtOH	Vanadyl acetylacetonate	N.A. 5	VO(Chry) ₂ EtOH	UV-Vis IR EPR Spectrophotometric titrations	[58]
	Ph₃GeBr	Na2CO3 N.A.	Chry-Ge. C ₂ H ₆ O	IR ¹ H & ¹³ C NMR Elemental analysis	[69]

	La acetate	NaOH <i>N.A</i> .	La(Chry)2.OAc(H2O)7	IR ¹ H NMR Elemental analysis TG-DTG Spectrophotometric titrations	[57]
Luteolin in H ₂ O	VOSO4.H2O	NaOH 6	VO(Lut) ₂	UV-Vis IR ¹ H NMR ESI-MS	[65]
Luteolin	50% aqueous solution of VOCl ₂	NaOH 5	[VO(Lut)(H ₂ O) ₂]Na·3H ₂ O	UV-Vis IR EPR Elemental analysis	[49]
Luteolin in EtOH	Mn(CH ₃ COO) ₂	<i>N.A.</i> 4	MnO-Lut	UV-Vis IR Elemental analysis TG-DTG	[70]
Hesperidin in H2O	50% aqueous solution of VOCl ₂	NaOH 12	[VO(Hesp)(OH) ₃]. Na ₄ (H ₂ O) ₃	UV-Vis IR EPR Spectrophotometric	[46]

				titrations	
Hesperetin in EtOH	CuCl ₂ .2H ₂ O	NH ₃ solution 7-8	[Cu(Hespt) ₂ (H ₂ O) ₂] ·H ₂ O	UV-Vis IR ESI-MS TG-DTG	[66]
Naringin in MeOH	Cu acetate in distilled H ₂ O	N.A.	[Cu (Nar)] ⁺ [CH ₃ COO] ⁻ ·(H ₂ O) ₅	UV-Vis IR ¹ H NMR ESI-MS Elemental analysis	[71]
Naringenin in EtOH	CuCl ₂ .2H ₂ O	NH ₃ solution 7-8	[Cu(Narg) ₂ (H ₂ O) ₂] ·H ₂ O	UV-Vis IR ESI-MS TG-DTG	[66]
Apigenin in EtOH	CuCl ₂ .2H ₂ O	NH ₃ solution 7-8	[Cu(Apg) ₂ (H ₂ O) ₂] ·H ₂ O	UV-Vis IR ESI-MS TG-DTG	[66]
Silibinin in EtOH	50% aqueous solution of VOCl ₂	NaOCH ₃ 9	Na ₂ [VO(Sil) ₂].(H ₂ O) ₆	IR EPR Spectrophotometric titrations	[47]


Morin in MeOH	50% aqueous solution of VOCl ₂	NaOCH ₃ 5	[VO(Mor) ₂ H ₂ O]. (H ₂ O) ₅	UV-Vis IR EPR Spectrophotometric titrations	[48]
Kaempferol in EtOH	ZnCl ₂ .2H ₂ O	NaCl 8-10	[Zn(Kaem) ₂ (H ₂ O) ₂] ·H ₂ O	UV-Vis IR ¹ H NMR ESI-MS Elemental analysis	[64]
Niffcoumar sodium salt in H2O	Ce(NO ₃) ₃ .6H ₂ O La(NO ₃) ₃ .6H ₂ O Nd(NO ₃) ₃ .6H ₂ O	N.A. 4-5	Ce(NS) ₃ . (H ₂ O) ₄ La(NS) ₃ . (H ₂ O) ₄ Nd(NS) ₃ . (H ₂ O) ₆	IR ¹ H NMR Elemental analysis	[72]
Niffcoumar in H2O	Aqueous solution of ZrCl4	NaOH 5	Zr(Niff)2(OH)4(H2O)5	IR ¹ H NMR Elemental analysis TG-DTG	[73]
Warfarin in H2O	Aqueous solution of ZrCl4	NaOH 5	Zr(War)2(OH)4(H2O)2	IR ¹ H NMR Elemental analysis TG-DTG	[73]

Coumachlor in H ₂ O	Aqueous solution of ZrCl4	NaOH 5	Zr(Coum) ₂ (OH) ₄ (H ₂ O) ₆	IR ¹ H NMR Elemental analysis TG-DTG	[73]
1 in 50% EtOH	GeO ₂ in deionized H ₂ O	NaOH 7	N.A.	UV-Vis IR ¹ H NMR MS Elemental analysis TG-DTG	[62]
2-11 in MeOH	[Ru(η6-p- cymene)Cl ₂] ₂ in CH ₂ Cl ₂	NaOMe <i>N.A</i> .	N.A.	¹ H & ¹³ C NMR Elemental analysis X-ray for (49, 51, 53, 55)	[67, 68]
15-18 in CH ₂ Cl ₂	[Ru(η6-p- cymene)Cl ₂] ₂ in CH ₂ Cl ₂	N.A.	N.A.	UV-Vis spectra IR ¹ H NMR FAB/EI-MS	[61, 68, 74]
7, 12-14 in EtOH	[Ru(DMSO)4Cl2] in EtOH	TEA N.A.	[Ru(DMSO) ₂ (7) ₂] ₂ NaNO ₃ (H ₂ O) ₂ [Ru(DMSO) ₂ (12) ₂] ₂ NaNO ₃ . H ₂ O [Ru(DMSO) ₂ (13) ₂]. (NO ₃) ₂ (H ₂ O) ₂ [Ru(DMSO) ₂ (14) ₂] ₂ NaNO ₃ (H ₂ O) ₅	IR ¹ H NMR ESI-MS Elemental analysis	[63]


18 in EtOH	La(NO ₃) ₃ .6H ₂ O	TEA N.A.	N.A.	UV-Vis spectra IR ¹ H NMR Elemental analysis TG-DAT	[42]
19 in H ₂ O	Aqueous solution of Ce La Nd	NaOH 5	Ce(19)(OH)(H ₂ O) ₂ La(19)(OH).H ₂ O Nd(19)(OH).H ₂ O	IR ¹ H & ¹³ C NMR Elemental analysis	[75]
20 in EtOH	Aqueous solution of K ₂ PtCl ₄	N.A.	cis - [Pt(20) ₂ Cl ₂]	IR ¹ H & ¹⁹⁵ Pt NMR	[44]

N.A.: Not available


. – .




21, M = Ni; 22, M = Cu




31, M = Cu; 32, M = Zn





29; M = Tm; 30, M = Y










































44, X = NO₂; 45, X = H; 46, X = Cl




48, R = H; 49, R = *p*-CH₃; 50, R = *p*-F; 51, R = *m*-F; 52, R = *o*-F; 53, R = *p*-Cl; 54, R = *m*-Cl; 55, R = *o*-Cl; 56, R = *p*-Br; 57, R = *m*-Br; 58, R = *p*-OCH₃; 59, R = *p*-NO₂; 60, R = *p*-NMe₂




64, R = Cl; 65, R = OCH₃; 66, R = NO₂;


 $67, \mathbf{R} = \mathbf{NMe}_2$




61, L = Cpd 15; 62, L = Cpd 16; 63, L = Cpd 17




68





69



71



Figure 6. Chemical structures of flavonoid metal complexes

177 Anti-oxidant activities of flavonoid metal complexes

Complexation of flavonoids with metals often increases the anti-oxidant activity of the parent flavonoids as shown in table 2. Metal complexes demonstrate enhanced activities in free radical scavenging assays such as DPPH (1,1-diphenyl-2-picrylhydrazyl radical), ABTS⁺ [2,20-azinobis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt)], H₂O₂, OH⁻ and O₂⁻⁻. Superoxide dismutase (SOD) like activity is often used to measure the anti-oxidant activities of the complexes as it is considered to be one of the body's first line free radical defense enzymes.

184 However, it is important to note that even where the complexes showed better SOD like activity

- than their free parents they are still far above the limit for good SOD like activity which is $IC_{50} \le$
- 186 $20 \,\mu M$.

Complex	Assay	Results	Ref
		Enhanced activity	
		at 120 µM,	
23		90%	
24		85%	
25	O2	84%	
26		97%	[55]
27		77%	
28		92%	
29		87%	
30		88%	
		quercetin = 42%	
		Enhanced activity	
	DPPH	at 100 µM, 45%	
22	DPPH [.]	chrysin = 18%	[5 0 7 6]
33 -		Enhanced activity	[58, 76]
	$ABTS^+$	3.96 mM	
		chrysin = 0.9 mM	


187 Table 2. Summary of anti-oxidant activities of reviewed flavonoids and their metal complexes

	SOD	$IC_{50} = 157 \ \mu M$		
	SOD	chrysin = no activity		
_		Enhanced activity		
	OH	at 100 µM, 75%		
		chrysin = 45%		
		Enhanced activity		
	DPPH ⁻	at 100 µM, 40%		
36		luteolin = 25%	[45]	
36		Enhanced activity	[65]	
	$ABTS^+$	at 10 µM, 64%		
		luteolin = 40%		
		Lower activity		
	DPPH ⁻	$IC_{50} = >100 \ \mu M$		
		$luteolin = 66.7 \mu M$		
		Enhanced activity		
37	OH	$IC_{50} = 17 \ \mu M$	[49]	
		luteolin = 50.7 μM		
_		Lower activity		
	O_2^{-}	$IC_{50}{=}417\;\mu M$		
		luteolin = $384 \mu M$		
		Enhanced activity		
	DPPH [.]	at 1 mM, 90%		
38 _		luteolin = 75%	[70]	
30 _		Enhanced activity	[/0]	
	OH	at 1 mM, 80%		
		luteolin = 74%		
VOhesperidin	DPPH [.]	No enhancement in	[46]	
	$ABTS^+$	activity	[46]	
		Enhanced activity		
40	DPPH ⁻	at 10 µM, 35.5%	[71]	
		naringin = 2%		

		Slightly enhanced	
		activity	
	SOD	$IC_{50} = 45 \ \mu M$	
		morin = 66 µM	
-		Similar activity	
	DPPH [.]	at 10 µM, 22%	
VOmerin		<i>morin = 15%</i>	г <i>и</i> от
VOmorin		Similar activity	[48]
	$ABTS^+$	at 10 µM, 81%	
		<i>morin = 76%</i>	
		Enhanced activity	
	OH	at 10 µM, 26%	
		<i>morin</i> = 2%	
	ROO	No effect on radical	
		Enhanced activity	
	OH	at 100 µM, 65%	
47		2 = 43%	
4/		Lower activity	[62]
	DPPH ⁻	at 80 µM, 60%	
		2 = 95%	

As shown in table 2, rare earth metal complexes (23-30) increased O_2^{-1} scavenging activity of 189 quercetin by, on average, 2-fold [55]. The difference in activity between the eight metal 190 complexes is not significant, however, the gadolinium complex (26) showed the best activity. 191 192 Whether this increase in activity is attributed to incorporation of the metal atom or to the higher molar ratio of quercetin present in the complex (as opposed to 1 quercetin molecule) needs 193 further investigation. Figure 7 illustrates the main structural features responsible for the anti-194 oxidant activity of flavonoids. The 3', 4' ortho-dihydroxyl group is the most significant 195 contributor to flavonoids' anti-oxidant activity [3]. These two catechol moieties form ortho-196 semiquinone radicals that are highly stabilized by the electron delocalization and intra-molecular 197 hydrogen bonding. The combination of C2=C3 and 4-C=O group in ring C also assists in the 198

199 delocalization of the π -electrons in ring B. This in turn influences the dissociation of phenolic hydroxyl groups as well as the stability of the formed phenoxy radicals in ring B [3]. Ring A 200 201 meta-hydroxyl groups are less important than ring B dihydroxyl groups which are oxidized more readily [77]. The highest increase in activity can be seen upon complexation of metals with 202 203 flavonoids lacking the essential structural features of anti-oxidant activity (Figure 7), such as chrysin and naringin [78]. For instance, complexation of vanadium metal with chrysin (33) 204 205 increased ABTS⁺⁺ scavenging activity from 0.9 mM for chrysin to 3.96 mM [58]. This value is close to that of quercetin (4.7 mM) [79] that fulfills anti-oxidant structural activity requirements 206 (Figure 7) and is therefore one of the best flavonoid anti-oxidants. 207




208


Figure 7. Summary of structural features responsible for anti-oxidant activity of flavonoids

As illustrated in **Figure 8**, metal complexation demonstrated a positive impact on the DPPH⁻ 210 scavenging activity of ligands which was higher than that of vitamin C in only one case, the Cu-211 Naringin complex 40. Despite the witnessed increase in DPPH scavenging activity of chrysin 212 213 (18%) upon complexation with vanadium (33) (45%) at 100 μ M, it is still far less than that of ascorbic acid (98%) at the same concentration [58]. However, metal complexation did not 214 always result in enhanced DPPH scavenging activity. The vanadium-luteolin complex 37 215 showed a loss in the DPPH scavenging activity of luteolin due to chelation of the vanadium 216 217 metal with the 3' and 4'-OH groups that are essential for anti-oxidant activity of flavonoids [49]. Pi et al. attributed the loss of the polyphenol ligand's (2) high DPPH⁻ scavenging activity (95%) 218

after coordination with germanium (47) to steric hindrance factors [62]. This might be caused by



220 the presence of the two ethyl ether groups rather than the germanium atom.



224 Cytotoxic activities of flavonoid metal complexes

225 One of the milestones in the history of chemotherapy was the discovery of cisplatin in 1969 [80]. Cisplatin is effective and still widely used against various types of cancers, such as testicular, 226 ovarian, breast, bladder, lung cancer and brain tumors. It demonstrates remarkable curing rates 227 for testicular cancer (over 90% and near 100% with early discovery) [81]. Inside the body, 228 229 cisplatin crosslinks DNA and initiates apoptosis. Despite this promising profile, cisplatin suffers from limitations such as nephrotoxicity, neurotoxicity and drug resistance [82, 83]. This ongoing 230 231 interest in the design and development of metal-based anti-cancer drugs has also influenced the flavonoid field, where a number of flavonoid-metal complexes have been synthesized and 232 233 evaluated as anti-cancer agents.

234

- 235
- 236

238 Cytotoxic activity of quercetin metal complexes

Complex	Cell line	Activity (μM) (IC ₅₀ or suppression % or GI ₅₀)	Quercetin activity (µM)	Ref.
	HepG2	14.4 ± 0.9 *	33.7 ± 1.0 *	
21	SMMC7721	19.6 ± 0.6 *	42.1 ± 1.0 *	[84]
	A549	35.6 ± 0.8 *	72.1 ± 1.2 *	
22	A549	21.5 ± 0.5 *	34.9 ± 1.0 *	[53]
23	Bel-7402	46.03% *	20% •	
25	Bel-7402	62.32% *	20% •	[55]
26	Bel-7402	45.30% *	20% •	
31	U373MG, PC3, Hop62, HL60, HCT15 and HeLa	< 8.7 •	N.A.	[43]
32	HeLa	7.7 •	N.A.	


Table 3. Summary of *in vitro* anti-tumor activity of quercetin metal complexes

240 * = IC₅₀, \blacklozenge = Suppression % at 10 μ M, \blacklozenge = GI₅₀

Hepatocellular carcinoma (HepG2), hepatoma (SMMC7721), lung carcinoma (A549), liver cancer (Bel7402), central nervous system (U373MG), prostate cancer (PC3), lung cancer (Hop62), leukemia
(HL60), colon carcinoma (HCT15) and cervical cancer (HeLa).

244

It is evident that complexation with metals enhances the anti-proliferative activity of quercetin. 245 246 Compound 21 (Ni-quercetin) had better activity on the hepatic cancer cell lines (HepG2 and 247 SMMC7721) than on the lung carcinoma cell line (A549). Pro-apoptotic ability has been investigated for complexes 21 and 22 (Cu-quercetin) as a possible cytotoxic mechanism (Figure 248 9) [53, 84]. This is indicated by changes in the levels of key apoptotic proteins like survivin and 249 250 caspases along with morphological changes observed using the DNA-sensitive Hoechst33258 251 stain. Possible mechanisms of action of **21** on the A549 cell line were not evaluated. This might have given a better idea of the behavior of complexes in different cell lines and the reasons 252 253 behind the witnessed difference in activities.



254

Figure 9. Summary of pro-apoptotic studies done on complexes 21 and 22. Survivin expression
 was measured by immunocytometry and caspase activity by absorption spectra.

Metal atoms in flavonoid complexes can interact with DNA nucleotides by either electrostatic 258 259 interactions with the phosphate groups, or covalent binding to nucleobases (Figure 10). The ROS and free radicals resulting from flavonoids' auto-oxidation are thus generated in proximity 260 to the DNA [37]. This leads to oxidative damage of DNA and induces apoptosis (Figure 10) [85, 261 86]. Flavonoid metal complexes are also more planar than the free ligands which facilitates their 262 binding to DNA via intercalation [37]. Tan et al. reported the selective binding of the nickel 263 264 quercetin complex (21) to GC-rich DNA sequences using fluorescence emission and molecular modelling. This, in addition to decreased survivin activity, led them to conclude that down 265 regulation of survivin via interference with the GC-rich survivin protein promoter gene might be 266 a plausible mechanism by which the complex 21 exerts its anti-tumor activity [84]. 267






Figure 10. Plausible mechanism of oxidative DNA damage by flavonoid metal complexes

270 The quercetin rare earth metal complexes (23, 25 and 26) showed increased activities compared with free quercetin on the liver cancer cell line (Bel-7402) (Table 3) [55]. Complex 23 (La-271 quercetin) can intercalate with DNA as evidenced by DNA fluorescence studies. Tabassum and 272 her colleagues were able to synthesize two unique hetero-bimetallic complexes quercetin-Cu^{II}-273 Sn_2^{IV} (31) and quercetin– Zn^{II} – Sn_2^{IV} (32) [43]. The Cu complex (31) showed significant activity 274 on various human cancer cell lines (Table 3) except for ovarian cancer (A2780). The Zn 275 complex (32), however, did not demonstrate good activity except on the HeLa cell line (Table 276 3). Complexes 22, 31 and 32 were able to promote the conversion of substrate DNA to cleaved 277 forms (nicked and linear) as studied by gel electrophoresis [43, 53, 54]. To better understand 278 279 whether this DNA cleavage is promoted through an oxidative pathway, the effect of different 280 radical scavengers was evaluated where only H_2O_2 markedly promoted plasmid DNA breakage caused by the complexes. Increased level of thiobarbituric acid reactive species (TBARS) with 281 increasing concentrations of complex 22 backs up the role of oxidative damage as a mechanism 282 283 of CT-DNA cleavage [53, 54]. At 30 µM of complex 31, DNA relaxation activity of 284 Topoisomerase-I was significantly inhibited. This does not necessarily correlate with direct inhibition of the enzyme and may instead result from strong binding with DNA which prevents 285 286 the enzyme from exercising its function [43]. To exploit binding of complexes 31 and 32 with the minor groove of DNA, the complexes were docked into the DNA duplex of sequence 287 d(CGCGAATTCGCG)2 dodecamer (PDB ID: 1BNA). Both complexes bound to the narrow 288 minor groove region of DNA within the GC rich region and were stabilized by hydrogen 289 bonding (2.8-3.0 Å) between the -OH groups of quercetin with O4/N2 atoms of C8/G8 bases in 290 291 DNA.

292 Complex **31** also showed good binding modes with the human-DNA–Topo-I complex (PDB ID:

1SC7) and bovine erythrocyte Cu, Zn superoxide dismutase (PDB ID: 2SOD) [43].

294 Cytotoxic activity of chrysin, luteolin and silibinin metal complexes

Table 4. Summary of *in vitro* anti-tumor activity of metal complexes of chrysin, luteolin and

296 silibinin

Complex	Cell line	Activity (μM) (IC ₅₀ or suppression %)	Flavonoid activity (µM)	Ref.	
33	MG-63	16 *	>100 *	[76]	
55	HT-29	45% [◊]	No effect [◊]	[87]	
VOsilibinin	HT-29	45% [◊]	No effect [◊]	[07]	
	HepG2	30% *	20% •		
	Colo205	25% *	10% *	[(0)]	
	MCF-7	45% *	20% *	[69]	
	MCF-7 10A	15% *	10% •		
35	A549	73.5 % *	4.9 % *	[57]	
27	A549	60.5 *	66.3 *	[40]	
37	MDAMB-231	17 *	88.3 *	[49]	

297 * = IC₅₀, \blacklozenge = Suppression % at 10 µM, \diamondsuit = Suppression % at 100 µM

Osteosarcoma (MG-63), colon adenocarcinoma (HT-29), hepatocellular carcinoma (HepG2), caucasian
 colon adenocarcinoma (Colo205), breast cancer (MCF-7), breast cell line (MCF-7 10A), lung carcinoma
 (A549) and triple negative breast cancer (MDAMB-231).

302 The vanadium chrysin complex (33) showed significant cytotoxic activity on a human osteosarcoma cell line (MG-63) with an IC₅₀ value of 16 μ M (**Table 4**) [76]. This activity is 303 304 higher than the reported activity of cisplatin on the same cell line (IC₅₀ = 28.5 μ M), yet lower than that of doxorubicin (IC₅₀ = 3.35μ M) [88]. According to Leon et al. complex **33** showed a 305 multi-factorial anti-tumor mechanism of action. For example, it demonstrated cytotoxicity to 306 lysosomes and mitochondria of MG-63 cell line (at concentrations from 2.5 to 25 µM) as 307 evidenced using neutral red (NR) uptake and the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-308 diphenyltetrazolium bromide (MTT) assays, respectively. Genotoxicity was also evident through 309 induced micronuclei formation and DNA breaks using the Comet assay, in the concentration 310 range 2.5-5 µM. In addition to that, compound **33** lowered GSH/GSSG ratio in MG-63 cell line 311 especially at higher doses (40%, 50 and 100 µM). In a protein array platform test, 33 upregulated 312 82 proteins and downregulated 9 such as PKB/AKT, Cdk 4, 6 and 7, NAK, and JNK [89]. It 313 induced apoptosis via: 314

- Externalization of the phosphatidyl serine (PS), at the outer plasma membrane leaflet
 measured by Annexin V-FITC fluorescent probe.
- 317

Alteration of the mitochondria membrane potential (MMP) measured by Rhodamine 123 that
 leads to the release of cytochrome c and finally to DNA fragmentation.

320

• Activation of caspase pathway measured by caspase 3 activation (350% basal at 100μ M).

322

In another report the anti-tumor activities of vanadium complexes of chrysin (33) and silibinin 323 324 (VOsil) were tested on the HT-29 cell line (Table 4) [87]. 33 and VOsil showed better anti-325 proliferative activities than cisplatin at 100 μ M (inhibition rate = 12 %) on the same cell line. However, 33 did not show pro-apoptotic effects in the MG-63 cell line despite it causing cell 326 cycle arrest in the G2/M phase after 24 and 48 hours incubation. VOsil, on the other hand, 327 increased the percentages of apoptotic/necrotic cells, induced caspase 3 activation and reduced 328 329 nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) that controls DNA transcription and is aberrantly activated in many cancers. Moreover, VOsil fully inhibited 330 331 topoisomerase-IB using plasmid relaxation assay at 100 µM. The germanium complex of chrysin, (34) also had activity on several targets. Its cytotoxic effect on HepG2, Colo250 and 332 333 MCF-7 cell lines was not significantly high nor much better than chrysin [69, 90]. The mean apoptotic population detected on MCF-7 and Colo205 cell lines by Annexin-V were 19.5% and 334

12.5% for 20 µg/ml, respectively. Additionally, cellular ROS production increased in MCF-7 335 cell line upon addition of high doses of complex 34. This could be a possible etiology for 336 337 apoptosis alongside with caspase-3, 8 and 9 activation whose levels increased from 100% to 214.5%, 181.1% and 286.0%, respectively at 20 µg/ml. Some caspase activation was also 338 observed on the Colo205 cell line with an increase from 100% to 129.3%, 146.5 and 119.3%, for 339 caspase-3, 8 and 9, respectively. Cell cycle arrest at the G2/M phase was detected on MCF-7 and 340 Colo205 (high doses) cell lines and at the S phase with low doses of the complex on the Colo205 341 cell line. Complex 35 (La-chrysin) showed a significant increase (73.5%) in the anti-proliferative 342 activity of chrysin (4.9%) on A549 cell lines. The complex intercalated with DNA base pairs as 343 illustrated by an increase in viscosity and fluorescence of DNA upon addition of complex 35 344 [57]. The vanadium luteolin complex (37) significantly improved the cytotoxic activity of its 345 parent on the MDAMB-231 cell line (IC₅₀ = 17 μ M) as shown in table 4 [49]. However, it 346 showed a trivial improvement on the A549 cell line (IC₅₀ = 60.5 μ M, luteolin IC₅₀ = 66.3 μ M). 347 Naso et al. carried out high content cytotoxicity assays on complex 37 to investigate its 348 mechanism of action on the MDAMB-231 cell line. The tests included ROS production, MMP, 349 350 plasmatic membrane damage, nuclear membrane damage and mitotic arrest. Complex 37 showed significant increase in the levels of ROS production (650%) and percentage of depolarized cells 351 352 (20%). Lactate dehydrogenase (LDH) levels in the culture media were measured as an indication for plasmatic membrane damage. Complex 37 demonstrated 212% increase compared with the 353 354 basal levels as opposed to 98% for luteolin. The vanadium complex (37) also showed DNA damage and mitotic arrest activities using H2AX and PHH3 assays, respectively. 355

Cytotoxic activity of hesperidin, naringin, hesperitin, naringenin, apigenin, morin, kaempferol, warfarin and mendiaxon metal complexes

358

Table 5. Summary of *in vitro* anti-tumor activity of hesperidin, naringin, hesperitin, naringenin,
 apigenin, morin, kaempferol, warfarin and mendiaxon metal complexes.

Complex	Cell line	Activity (suppression %)	Flavonoid Activity	Ref.
VOhesperidin	Caco-2	60% (at 100 µM)	No effect	[46]
40	K562	38.4% (at 100 µM)	13.2% (at 100 µM)	[71]
La-18 _	HL60	50% (at 0.01 µM)	N.A.	[42]
	A549	100% (at 0.003 µM)	N.A.	

HeLa	22.5%	15%	
SGC-7901	45%	30%	
HepG2	45%	30%	
HeLa	24%	27%	[66]
SGC-7901	25%	33%	
HepG2	35%	15%	
HeLa	25%	10%	
SGC-7901	45%	5%	
HepG2	35%	5%	
T47D	43% (at 10 µM)	No effect	[48]
SKBR3	38% (at 10 µM)	14% (at 10 µM)	
EC9706	72% (at 30 µg/ml)	45 % (at 30 µg/ml)	[64]
HL60	30% (at 100 µM)	N.A.	[73]
	SGC-7901 HepG2 HeLa SGC-7901 HepG2 HeLa SGC-7901 HepG2 TeLa SGC-7901 SGC-7901 SGC-7901 SGC-7901 SGC-7901 HepG2 SGC-7901 HepG2 T47D SKBR3 EC9706	SGC-7901 45% HepG2 45% HeLa 24% SGC-7901 25% HepG2 35% HeLa 25% SGC-7901 45% HepG2 35% HeLa 25% SGC-7901 45% FepG2 35% SGC-7901 45% SGC-7901 43% (at 10 µM) SKBR3 38% (at 10 µM) EC9706 72% (at 30 µg/ml)	SGC-790145%30%HepG245%30%HeLa24%27%SGC-790125%33%HepG235%15%HeLa25%10%SGC-790145%5%HepG235%5%HepG235%5%T47D43% (at 10 μM)No effectSKBR338% (at 10 μM)14% (at 10 μM)EC970672% (at 30 μg/ml)45% (at 30 μg/ml)

Colon adenocarcinoma (Caco-2), chronic myeloid leukemia (K562), leukemia (HL60), lung carcinoma (A549), cervical carcinoma (HeLa), gastric carcinomas (SGC-7901) and hepatocellular carcinoma (HepG2), breast cancer (T47D), breast cancer overexpressing Herceptin-2 (SKBR3) and oesophageal cancer cell line (EC9706).

365 As shown in table 5, VOhesperidin showed 60% inhibition in cellular proliferation of the colon 366 367 adenocarcinoma cell line (Caco-2) while its parent hesperidin showed no effect at all on the same 368 cell line at 100 μ M [46]. The Cu naringin complex (40) exhibited better inhibition of the K562 cell lines (Table 5). Cell cycle analysis showed a 50% decrease in viable cells at the S/G2/M 369 phases after 24 h. The number of hypodiploid cells tremendously increased from 5.5% (control) 370 371 to 38.4% indicating the complex led to cell death in the first 24 h [71]. The lanthanum complex with ligand 18 exhibited a stronger suppression rate (100% inhibition at 0.003 μ M) than cisplatin 372 (100 % inhibition at 0.004 µM) on the A549 cell line [42]. Lanthanum complexes like 35 and 373 La-18 have significantly high suppression rates on A549 cell line. 374

As shown in table 5, complexation of copper with the flavonoids hesperetin (**39**) and apigenin (**42**) did enhance the anti-proliferative activity of their free flavonoids whilst the naringenin complex (**41**) did not show any improvement except on the HepG2 cell line [66]. **41** and **42** had the same suppression rate (35%) on the HepG2 cell line. This indicates that unsaturation of ring C has no effect on the activity whilst the addition of an OH group on ring B, as in complex **39**, results in 30% increase in the activity. This may be due to the enhanced anti-oxidant activity of compounds featuring two *m*-hydroxyl groups on ring B (Figure 7). Several DNA binding studies
 (UV-Vis spectral, fluorescence and CD measurements) were performed with the complex 39 that
 indicated DNA binding via intercalation with higher affinity than the free ligand.

The vanadium morin complex (VOmor) showed promising cytotoxic activity on human breast 384 cancer cell lines (Table 5). It did not have deleterious effects on the non-tumorigenic breast 385 epithelial mammal cells indicating its selectivity towards cancer cells [48]. Naso et al. suggest 386 that the VOmor complex causes cell death by induction of apoptosis. This can be correlated to 387 perturbation of the mitochondrial membrane potential which results in release of cytochrome c 388 from the mitochondria to cytosol. This process leads to the activation of caspases-9, 3 and 7. 389 However, mitochondrial membrane potential was only observed in the SKBR3 cell line which 390 suggests the apoptotic potential on the T47D is achieved via a different mechanism that needs 391 further investigation. The MTT assay was used to determine the anti-proliferative activity of the 392 Kaempferol Zn complex (43) on EC9706 cells (Table 5) [64]. Cell viability decreased nearly by 393 half in the EC9706 cell line while no significant effect was observed on the normal kidney cells 394 (HK-2 cells). Atomic force microscopy (AFM) morphological data showed that complex 43 395 396 could deform and shrink EC9706 cells at the nanoscale. To measure apoptosis induction ability, Annexin V-FITC/PI was used. The apoptosis ratio of EC9706 cells increased from $3.4 \pm 0.9\%$ 397 for control cells to $33 \pm 7.6\%$ upon raise of **43** concentrations from 0 to 30 µg/mL, respectively. 398 Complex 43 was able to increase the intracellular calcium ion level in cancer cells that can 399 400 mediate cell death.

401 Cytotoxic activity of metal complexes 47-71

Complex	Cell line	Activity (µM) (IC ₅₀ or suppression%)	Flavonoid activity (µM)	Ref.
47	HepG2	65% •	35% *	
51	CH1	1.5 *	N.A.	
53		0.86 *	0.6 *	- [(7, (9)]
54		1 *	N.A.	[67, 68]
55		1.2 *	N.A.	
61	DMBC12	0.96 *	N.A.	[61]

Table 6. Summary of *in vitro* anti-tumor activity of complexes **47-71**

62		1.13 *	<i>N.A.</i>	
63		2.53 *	N.A.	
03	DMBC11	4.14 *	N.A.	
64	MCF-7	16 *	17.2 *	
65		28 *	29.5 *	[(2)]
66		32.1 *	35.4 *	[63]
67		36.2 *	38.4 *	
Ce-19	HL60	21.37 *	N.A.	[75]
69	CCRF-CEM	37.5 *	N.A.	[41]
70	Jurkat	2.97 *	N.A.	
70 _	HeLa	7.23 *	N.A.	[91]
71		7.4 *	N.A.	

403 $* = IC_{50}, \blacklozenge =$ Suppression % at 160 μ M

408

Hepatocellular carcinoma (HepG2), ovarian cancer (CH1), patient derived (not-established) melanoma
(DMBC11 and DMBC12), breast cancer (MCF-7), lung carcinoma (A549), cervical carcinoma (HeLa),
chronic myelogenous leukemia (K562), leukemia (HL60), T lymphoblast-like polymorph cancerous cell
line (CCRF-CEM) and acute T-lymphoblastic leukemia (Jurkat)

Pi et al. reported the DNA binding of the germanium complex of compound 1 (47) [62]. 409 410 Compound 47 showed an increase in fluorescence emission by 46% (at 550 nm) while that of the 411 free parent 1 showed insignificant increase by 8% (at 536 nm). Intercalation with DNA was also confirmed by a UV absorption method through the hypochromism of complex 47 upon addition 412 of CT-DNA. The anti-proliferative evaluation of 47 on the HepG2 cell line (Table 6) was 413 followed by AFM that showed deformation of HepG2 cells and increase in the size of cell 414 415 membrane particles. The effect on cell cycle, measured by flow cytometry, demonstrated that complex 47 causes cell cycle arrest at the G0/G1 phase. 416

The ruthenium complexes **48-57** were tested on a number of human cancer cell lines; CH1 (ovarian carcinoma), SW480 (colon carcinoma), and A549 (non-small cell lung carcinoma), human urinary bladder (5637), human large cell lung (LCLC-103H), and human pancreatic carcinoma cell lines (DAN-G) [67, 68]. The most significant anti-proliferative activities were observed on the CH1 cell line with IC₅₀ values ranging from 0.89 to 7.9 μ M (**Table 6**) [67]. The SW480 cell line also showed high sensitivity to these complexes (IC₅₀ from 3.4 - 26 μ M) while A549 was the least affected with moderate activities (IC₅₀ from 8.6 - 30 μ M). Kurzwernhart et al. 424 attempted to determine the mode of action of complexes 48-57 via CDK2 and topoisomerase IIa inhibition assays as well as flow cytometry cell cycle analysis. Despite showing inhibition of 425 426 CDK2 comparable with the standard reference roscovitine, CDK2 inhibition was excluded by the authors as a mechanism of action. This is due to miscorrelation with the *in vitro* anti-tumor assay 427 activity pattern and poor influence on the G1/S transition of the cell cycle in which CDK2 is 428 involved. On the other hand, complexes 48-57 showed good inhibition of topoisomerase IIa 429 430 catalytic activity at $\geq 10 \ \mu$ M, which correlated well with the cytotoxic activity (compounds with lowest IC_{50} in MTT assay showed the highest topoisomerase IIa inhibition). 431

Compounds 61-63 showed promising IC_{50} values on the patient derived (not-established) 432 433 melanoma cell lines (DMBC11 and DMBC12) as shown in table 6 [61]. Only complex 63 exhibited potency on both DMABC11 and DMBC12 cell lines (IC₅₀ = 2.53 and 4.14 μ M, 434 respectively). Singh et al. developed four flavonoid ruthenium DMSO complexes (64-67) and 435 tested their anti-proliferative activities on the MCF-7 cell line (Table 6) in addition to their 436 437 action on different phases of the cell cycle [63]. Both the free ligands, and their ruthenium complexes, showed similar activities with complex 64 being the most potent with $IC_{50} = 16 \mu M$. 438 439 Analysis of the cell cycle showed that compound 64 dramatically increased the G1 phase and decreased the S phase which might be explained by G1 arrest via inhibition of DNA synthesis in 440 441 the S phase.

Kostova et al. tested the cytotoxicity of three metal complexes (Cerium, lanthanum and
neodymium) with a bis-coumarin (19) [75]. Only the cerium complex demonstrated promising
anti-proliferative effect on the HL-60 cell line (Table 6).

Among four ferrocenylvinyl-flavone derivatives synthesized by Kowalski et al., compound **69** was the most potent (**Table 6**) [41]. The mechanism of action was induction of apoptosis and necrosis as shown by double staining of cells with Hoechst 33258 and propidium iodide. Although anti-tumor activity was evaluated on four human cancer cell lines (HepG2, MCF-7, MDA-MB-231 and CCRF-CEM), CCRF-CEM was the only affected cell line.

Janka and his colleagues also developed a number of ferrocenyl chalcones of which compound 70 showed high activity on Jurkat cell line with $IC_{50} = 2.97 \mu M$ (**Table 6**) [91]. Complex **71** has an additional ferrocenyl-vinyl group in its structure, however, it didn't show increase in the

35

453 activity on the HeLa cell line (IC₅₀ = 7.4 μ M) when compared with complex **70** (IC₅₀ = 7.23 μ M).




Figure 11. Summary of the effect of chelating different metals on the anti-proliferative activities
 of parent flavonoids

458 It can be deduced from **Figure 11** that 64% of the complexes showed enhanced anti-proliferative activities when compared to their parents while 11% maintained the same activity and 25% had 459 460 lower activity. It should be noted that not all of the complexes' activities were compared to their respective parent flavonoid, depending on the availability of data. All of iron, zinc and 461 462 germanium complexes showed higher activity than the free flavonoids. However, the total number of zinc complexes is too low to establish a clear view on the effect of complexation. On 463 464 the other hand, 84%, 69% and 62% of the vanadium, copper and lanthanum complexes, respectively, exhibited better anti-proliferative activities than the free flavonoid. Ruthenium 465 466 metal complexes showed inconsistent results as 36% showed enhanced activity while 21% had the same activity and 43% showed lower activities than their parent flavonoids. 467

468

469 **Future perspectives**

470

Flavonoids have gained significant interest from researches since the early times. This is due to their therapeutic activities in a broad range of fields alongside their natural abundance, with the anti-oxidant and anti-cancer effects of flavonoids being of the greatest impact. Consequently, flavonoids like quercetin and flavopiridol have reached clinical trials as anti-cancer agents. However, none of them are available on the market as anti-cancer drugs due to their poor

pharmacokinetic profiles. The structural ability of flavonoids to coordinate with metal atoms has 476 provided a new strategy for the development of flavonoid metal complexes with better 477 pharmacological profiles. Although chelation of flavonoids with metals enhanced the anti-478 479 oxidant and anti-proliferative activities of their free parents in the majority of cases reported herein, more research is needed to confirm if this is a predictable and general phenomenon. 480 Additionally, more research is required to probe whether this enhancement of activity is 481 482 sufficient to afford new drugs that offer enhanced clinical outcomes when compared to drugs present in the market for the same indications. Larger scale studies probing the impact of 483 complexing different metal atoms with sets of structurally similar and/or different flavonoids on 484 anti-oxidant and anti-proliferative activities are therefore greatly needed. This would pave the 485 way for a better understanding of their structural activity relationships. Furthermore, the use of 486 computational studies like molecular modelling and quantitative SAR (QSAR) can provide 487 valuable information about possible targets and mechanisms of action of these complexes. This 488 489 will in turn lead to well informed and targeted structural designs.

490 **Executive summary**

491 Introduction

- Flavonoids are polyphenolic compounds with a C_6 - C_3 - C_6 ring system.
- Flavopiridol, silibinin and quercetin flavonoids have reached clinical trials as anti-cancer
 agents for various tumors.
- Flavonoids have poor pharmacokinetic properties which limit their clinical applications.
- Flavonoids have the ability to form metal complexes that can change their pharmacological
 and pharmacokinetic properties.
- 498

499 Synthesis and characterization of flavonoid metal complexes

- Flavonoid metal complexes are synthesized by reacting alcoholic or aqueous solutions of both
 the flavonoid and the metal under stirring and/or heating conditions.
- Structural characterization techniques of flavonoid metal complexes are versatile and are often
 complementary to one another.
- 504

505 Anti-oxidant activities of flavonoid metal complexes

- Flavonoid metal complexes demonstrate better radical scavenging activities than their free parents.
- Anti-oxidant activity is measured by the ability to scavenge free radicals like DPPH⁻, ABTS⁺,
- 509 H_2O_2 , OH⁻ and O_2^{--} in addition to measuring SOD like activity.

- Some flavonoid metal complexes showed DPPH⁻ scavenging activity higher or comparable to vitamin C.
- 512

513 Cytotoxic activities of flavonoid metal complexes

- The discovery of cisplatin had an important role in directing researchers' focus on the
 development of metal based drugs.
- Flavonoid metal complexes showed promising results on various human cancer cell lines.
- Cytotoxic activity of flavonoid metal complexes is caused by induction of apoptosis and/or
 oxidative damage of DNA.
- 64% of the flavonoid metal complexes showed better anti-proliferative activities than their
 parents, 11% maintained the same activity and 25% had lower activity.
- 521

522 **Financial disclosure**

- 523 MK is grateful to the Newton-Mosharafa Fund for a scholarship that has funded
- 524 her PhD studies.

525 **References**

- Isoda H, Motojima H, Onaga S, Samet I, Villareal MO, Han J. Analysis of the erythroid differentiation effect of flavonoid apigenin on K562 human chronic leukemia cells. *Chem. Biol. Interact.* 220, 269-277 (2014).
- 529 2. Perez-Vizcaino F, Fraga CG. Research trends in flavonoids and health. *Arch. Biochem.*530 *Biophys.* 646, 107-112 (2018).
- 3. Wang T-Y, Li Q, Bi K-S. Bioactive flavonoids in medicinal plants: Structure, activity
 and biological fate. *Asian J. Pharm. Clin. Res.* 13(1), 12-23 (2018).
- Jeong HJ, Ryu YB, Park S-J *et al.* Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. *Bioorg. Med. Chem.* 17(19), 6816-6823 (2009).
- 536 5. Kwon H-J, Kim H-H, Ryu YB *et al.* In vitro anti-rotavirus activity of polyphenol
 537 compounds isolated from the roots of Glycyrrhizauralensis. *Bioorg. Med. Chem.* 18(21),
 538 7668-7674 (2010).
- 539 6. Sithisarn P, Michaelis M, Schubert-Zsilavecz M, Cinatl Jr J. Differential antiviral and
 540 anti-inflammatory mechanisms of the flavonoids biochanin A and baicalein in H5N1
 541 influenza A virus-infected cells. *Antivir. Res.* 97(1), 41-48 (2013).

- 542 7. Guz NR, Stermitz FR, Johnson JB *et al.* Flavonolignan and Flavone Inhibitors of a
 543 Staphylococcus a ureus Multidrug Resistance Pump: Structure– Activity Relationships. *J.*544 *Med. Chem.* 44(2), 261-268 (2001).
- 545 8. Kim YS, Ryu YB, Curtis-Long MJ *et al.* Flavanones and rotenoids from the roots of
 546 Amorpha fruticosa L. that inhibit bacterial neuraminidase. *Food Chem. Toxicol.* 49(8),
 547 1849-1856 (2011).
- 548 9. Ohemeng K, Schwender C, Fu K, Barrett J. DNA gyrase inhibitory and antibacterial activity of some flavones (1). *Bioorg. Med. Chem. Lett.* 3(2), 225-230 (1993).
- Wu T, He M, Zang X *et al.* A structure–activity relationship study of flavonoids as
 inhibitors of E. coli by membrane interaction effect. *Biochim. Biophys. Acta (BBA)- Biomembr.* 1828(11), 2751-2756 (2013).
- Eghorn LF, Hoestgaard-Jensen K, Kongstad KT *et al.* Positive allosteric modulation of
 the GHB high-affinity binding site by the GABAA receptor modulator monastrol and the
 flavonoid catechin. *Eur. J. Pharmacol.* 740, 570-577 (2014).
- Gopinath K, Sudhandiran G. Naringin modulates oxidative stress and inflammation in 3 nitropropionic acid-induced neurodegeneration through the activation of nuclear factor erythroid 2-related factor-2 signalling pathway. *Neuroscience*. 227, 134-143 (2012).
- Spencer JP, Vafeiadou K, Williams RJ, Vauzour D. Neuroinflammation: modulation by flavonoids and mechanisms of action. *Mol. Aspects Med.* 33(1), 83-97 (2012).
- Guo L, Hu W-R, Lian J-H *et al.* Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo. *Eur. J. Pharmacl.* 551(1-3), 80-86 (2006).
- Li G, Zhu Y, Zhang Y, Lang J, Chen Y, Ling W. Estimated daily flavonoid and stilbene
 intake from fruits, vegetables, and nuts and associations with lipid profiles in Chinese
 adults. J. Acad. Nutr. Diet. 113(6), 786-794 (2013).
- 566 16. Greeff J, Joubert J, Malan SF, Van Dyk S. Antioxidant properties of 4-quinolones and
 567 structurally related flavones. *Bioorg. Med. Chem.* 20(2), 809-818 (2012).
- Hyun J, Woo Y, Hwang D-S *et al.* Relationships between structures of hydroxyflavones
 and their antioxidative effects. *Bioorg. Med. Chem. Lett.* 20(18), 5510-5513 (2010).
- 18. Xie P-J, Huang L-X, Zhang C-H, Zhang Y-L. Phenolic compositions, and antioxidant
 performance of olive leaf and fruit (Olea europaea L.) extracts and their structure–activity
 relationships. *J. Funct. Foods.* 16, 460-471 (2015).

- 19. Ravishankar D, Rajora AK, Greco F, Osborn HM. Flavonoids as prospective compounds for anti-cancer therapy. *Int. J. Biochem. Cell. Biol.* 45(12), 2821-2831 (2013).
- Ravishankar D, Watson KA, Greco F, Osborn HM. Novel synthesised flavone derivatives
 provide significant insight into the structural features required for enhanced antiproliferative activity. *RSC Adv.* 6(69), 64544-64556 (2016).
- Liu-Smith F, Meyskens FL. Molecular mechanisms of flavonoids in melanin synthesis
 and the potential for the prevention and treatment of melanoma. *Mol. Nutr. Food Res.*60(6), 1264-1274 (2016).
- 581 22. Klimaszewska-Wiśniewska A, Hałas-Wiśniewska M, Izdebska M, Gagat M, Grzanka A,
 582 Grzanka D. Antiproliferative and antimetastatic action of quercetin on A549 non-small
 583 cell lung cancer cells through its effect on the cytoskeleton. *Acta Histochem.* 119(2), 99584 112 (2017).
- 585 23. Mirossay L, Varinská L, Mojžiš J. Antiangiogenic effect of flavonoids and chalcones: An update. *Int. J. Mol. Sci.* 19(1), 27 (2017).
- Ravishankar D, Watson KA, Boateng SY, Green RJ, Greco F, Osborn HM. Exploring
 quercetin and luteolin derivatives as antiangiogenic agents. *Eur. J. Med. Chem.* 97, 259274 (2015).
- 590 25. Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. *Invest. New Drugs.* 17(3), 313-320 (1999).
- A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute
 Myeloid Leukemia https://ClinicalTrials.gov/show/NCT03441555 (April, 22).
- 594 27. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice.
 595 World J Gastroenterol. 17(18), 2288 (2011).
- A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva)
 and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
 https://ClinicalTrials.gov/show/NCT02146118 (May, 23).
- 599 29. Ferry DR, Smith A, Malkhandi J *et al.* Phase I clinical trial of the flavonoid quercetin:
 600 pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. *Clin. Cancer Res.*601 2(4), 659-668 (1996).
- 602 30. Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients
 603 With Prostate Cancer Undergoing Surgery https://ClinicalTrials.gov/show/NCT01912820
 604 (May, 7).

- Mulholland P, Ferry D, Anderson D *et al.* Pre-clinical and clinical study of QC12, a
 water-soluble, pro-drug of quercetin. *Ann. Oncol.* 12(2), 245-248 (2001).
- Wu J-W, Lin L-C, Hung S-C, Chi C-W, Tsai T-H. Analysis of silibinin in rat plasma and
 bile for hepatobiliary excretion and oral bioavailability application. *J. Pharmaceut. Biomed. Anal.* 45(4), 635-641 (2007).
- Beep A, Marwaha RK, Marwaha MG, Nandal R, Sharma AK. Flavopiridol as cyclin dependent kinase (CDK) inhibitor: a review. *New J. Chem.* 42(23), 18500-18507 (2018).
- Gugler R, Leschik M, Dengler H. Disposition of quercetin in man after single oral and
 intravenous doses. *Eur. J. Clin. Pharmacol.* 9(2-3), 229-234 (1975).
- Samsonowicz M, Regulska E, Kalinowska M. Hydroxyflavone metal complexesmolecular structure, antioxidant activity and biological effects. *Chem. Biol. Interact.* 273, 245-256 (2017).
- ** This article reviews the synthetic procedures, spectroscopic properties, biological activities
 and mechanisms of action of hydroxyflavone metal complexes.
- Kasprzak MM, Szmigiero L, Zyner E, Ochocki J. Proapoptotic activity in vitro of two
 novel ruthenium (II) complexes with flavanone-based ligands that overcome cisplatin
 resistance in human bladder carcinoma cells. *J. Inorg. Biochem.* 105(4), 518-524 (2011).
- Kasprzak MM, Erxleben A, Ochocki J. Properties and applications of flavonoid metal
 complexes. *RSC Adv.* 5(57), 45853-45877 (2015).
- ** This review discusses the different metal coordination patterns, structural properties and
 the various applications of flavonoid metal complexes.
- Grazul M, Budzisz E. Biological activity of metal ions complexes of chromones, coumarins and flavones. *Coord. Chem. Rev.* 253(21-22), 2588-2598 (2009).
- This review gives details about the mechanisms of action of some metals and flavonoid
 metal complexes in the treatment of several pathological conditions.
- 39. Monserrat J-P, Tiwari KN, Quentin L *et al.* Ferrocenyl flavonoid-induced morphological
 modifications of endothelial cells and cytotoxicity against B16 murine melanoma cells. *J. Organomet. Chem.* 734, 78-85 (2013).
- 40. Tiwari KN, Monserrat J-P, Hequet A *et al.* In vitro inhibitory properties of ferrocenesubstituted chalcones and aurones on bacterial and human cell cultures. *Dalton Trans.*41(21), 6451-6457 (2012).

- Kowalski K, Koceva-Chyła A, Szczupak Ł *et al.* Ferrocenylvinyl-flavones: Synthesis, structure, anticancer and antibacterial activity studies. *J. Organomet. Chem.* 741, 153-161 (2013).
- 42. Wang B-D, Yang Z-Y, Wang Q, Cai T-K, Crewdson P. Synthesis, characterization, cytotoxic activities, and DNA-binding properties of the La (III) complex with Naringenin Schiff-base. *Bioorg. Med. Chem.* 14(6), 1880-1888 (2006).
- 43. Tabassum S, Zaki M, Afzal M, Arjmand F. New modulated design and synthesis of quercetin–Cu II/Zn II–Sn 2 IV scaffold as anticancer agents: in vitro DNA binding profile, DNA cleavage pathway and Topo-I activity. *Dalton Trans.* 42(27), 10029-10041 (2013).
- 646 * This article offers the novel synthesis of bimetallic quercetin complexes. It provides a
 647 detailed explanation of their anti-cancer mechanism of action supported by the relevant
 648 biological assays and computational studies.
- 649 44. Ciesielska E, Studzian K, Zyner E, Ochocki J, Szmigiero L. DNA damage and apoptosis
 650 induction in L1210 cells by cis-diamminedichloroplatinum (II) and its new aminoflavone
 651 analogue. *Cellular Mol. Biol. Lett.* 5(2), 235-235 (2000).
- 45. Weil JA, Bolton JR. *Electron paramagnetic resonance: elementary theory and practical applications.* John Wiley & Sons, (2007).
- 46. Etcheverry SB, Ferrer EG, Naso L, Rivadeneira J, Salinas V, Williams PaM. Antioxidant
 effects of the VO (IV) hesperidin complex and its role in cancer chemoprevention. J. *Biol. Inorg. Chem.* 13(3), 435 (2008).
- 47. Naso LG, Ferrer EG, Butenko N *et al.* Antioxidant, DNA cleavage, and cellular effects of
 silibinin and a new oxovanadium (IV)/silibinin complex. *J. Biol. Inorg. Chem.* 16(4),
 659 653-668 (2011).
- 48. Naso LG, Lezama L, Rojo T *et al.* Biological evaluation of morin and its new oxovanadium (IV) complex as antio-xidant and specific anti-cancer agents. *Chem Biol Interact.* 206(2), 289-301 (2013).
- 49. Naso LG, Lezama L, Valcarcel M *et al.* Bovine serum albumin binding, antioxidant and anticancer properties of an oxidovanadium (IV) complex with luteolin. *J. Inorg. Biochem.* 157, 80-93 (2016).
- 50. Jurd L, Geissman T. Absorption spectra of metal complexes of flavonoid compounds. J.
 Org. Chem. 21(12), 1395-1401 (1956).

- 51. Selvaraj S, Krishnaswamy S, Devashya V, Sethuraman S, Krishnan UM. Flavonoid–
 metal ion complexes: a novel class of therapeutic agents. *Med. Res. Rev.* 34(4), 677-702
 (2014).
- 671 * This review summarizes the structural characterization techniques and biological
 672 significance of flavonoid metal complexes.
- 673 52. Ren J, Meng S, Lekka CE, Kaxiras E. Complexation of flavonoids with iron: structure
 674 and optical signatures. J. Phys. Chem. B. 112(6), 1845-1850 (2008).
- 53. Tan J, Wang B, Zhu L. DNA binding and oxidative DNA damage induced by a quercetin copper (II) complex: potential mechanism of its antitumor properties. *J. Biol. Inorg.*677 *Chem.* 14(5), 727-739 (2009).
- 54. Tan J, Zhu L, Wang B. DNA binding and cleavage activity of quercetin nickel (II) complex. *Dalton Trans*. (24), 4722-4728 (2009).
- 55. Zhou J, Wang L-F, Wang J-Y, Tang N. Synthesis, characterization, antioxidative and antitumor activities of solid quercetin rare earth (III) complexes. *J. Inorg. Biochem.*83(1), 41-48 (2001).
- 56. Etcheverry SB, Barrio DA, Williams PA, Baran EJ. On the interaction of the vanadyl
 (IV) cation with lactose. *Biol. Trace. Elem. Res.* 84(1-3), 227-238 (2001).
- 57. Zeng Y-B, Yang N, Liu W-S, Tang N. Synthesis, characterization and DNA-binding properties of La (III) complex of chrysin. *J. Inorg. Biochem.* 97(3), 258-264 (2003).
- 58. Naso L, Ferrer EG, Lezama L, Rojo T, Etcheverry SB, Williams P. Role of oxidative stress in the antitumoral action of a new vanadyl (IV) complex with the flavonoid chrysin in two osteoblast cell lines: relationship with the radical scavenger activity. *J. Biol. Inorg.*690 *Chem.* 15(6), 889-902 (2010).
- 691 59. Wang Q, Zhao L, Zhao H *et al.* Complexation of luteolin with lead (II): Spectroscopy characterization and theoretical researches. *J. Inorg. Biochem.* 193, 25-30 (2019).
- 693 60. Kostova I, Manolov I, Nicolova I, Konstantinov S, Karaivanova M. New lanthanide
 694 complexes of 4-methyl-7-hydroxycoumarin and their pharmacological activity. *Eur. J.*695 *Med. Chem.* 36(4), 339-347 (2001).
- 696 61. Pastuszko A, Majchrzak K, Czyz M, Kupcewicz B, Budzisz E. The synthesis,
 697 lipophilicity and cytotoxic effects of new ruthenium (II) arene complexes with chromone
 698 derivatives. J. Inorg. Biochem. 159, 133-141 (2016).

- 699 62. Pi J, Zeng J, Luo J-J, Yang P-H, Cai J-Y. Synthesis and biological evaluation of
 700 Germanium (IV)-polyphenol complexes as potential anti-cancer agents. *Bioorg. Med.*701 *Chem. Lett.* 23(10), 2902-2908 (2013).
- Singh AK, Saxena G, Arshad M. Synthesis, characterization and biological evaluation of
 ruthenium flavanol complexes against breast cancer. *Spectrochim. Acta A Mol. Biomol. Spectrosc.* 180, 97-104 (2017).
- Tu L-Y, Pi J, Jin H, Cai J-Y, Deng S-P. Synthesis, characterization and anticancer activity of kaempferol-zinc (II) complex. *Bioorg. Med. Chem. Lett.* 26(11), 2730-2734 (2016).
- Roy S, Mallick S, Chakraborty T *et al.* Synthesis, characterisation and antioxidant activity of luteolin–vanadium (II) complex. *Food Chem.* 173, 1172-1178 (2015).
- Tan M, Zhu J, Pan Y *et al.* Synthesis, cytotoxic activity, and DNA binding properties of
 copper (II) complexes with hesperetin, naringenin, and apigenin. *Bioinorg. Chem. Appl.*2009, (2009).
- 67. Kurzwernhart A, Kandioller W, BäChler S *et al.* Structure–activity relationships of
 714 targeted RuII (η6-p-Cymene) anticancer complexes with flavonol-derived ligands. *J.*715 *Med. Chem.* 55(23), 10512-10522 (2012).
- Kurzwernhart A, Kandioller W, Bartel C *et al.* Targeting the DNA-topoisomerase complex in a double-strike approach with a topoisomerase inhibiting moiety and covalent DNA binder. *Chem. Commun.* 48(40), 4839-4841 (2012).
- Yang F, Jin H, Pi J *et al.* Anti-tumor activity evaluation of novel chrysin–
 organogermanium (IV) complex in MCF-7 cells. *Bioorg. Med. Chem. Lett.* 23(20), 55445551 (2013).
- 70. Dong H, Yang X, He J, Cai S, Xiao K, Zhu L. Enhanced antioxidant activity,
 antibacterial activity and hypoglycemic effect of luteolin by complexation with
 manganese (II) and its inhibition kinetics on xanthine oxidase. *RSC Adv.* 7(84), 5338553395 (2017).
- 726 71. Pereira R, Andrades NE, Paulino N *et al.* Synthesis and characterization of a metal complex containing naringin and Cu, and its antioxidant, antimicrobial, antiinflammatory and tumor cell cytotoxicity. *Molecules.* 12(7), 1352-1366 (2007).
- 729 72. Manolov I, Kostova I, Konstantinov S, Karaivanova M. Synthesis, physicochemical
 730 characterization and cytotoxic screening of new complexes of cerium, lanthanum and
 731 neodymium with Niffcoumar sodium salt. *Eur. J. Med. Chem.* 34(10), 853-858 (1999).

- 732 73. Kostova I, Manolov I, Karaivanova M. Synthesis, physicochemical characterization, and
 733 cytotoxic screening of new zirconium complexes with coumarin derivatives. *Arch.*734 *Pharm.* 334(5), 157-162 (2001).
- 735 74. Pastuszko A, Niewinna K, Czyz M, Jóźwiak A, Małecka M, Budzisz E. Synthesis, X-ray structure, electrochemical properties and cytotoxic effects of new arene ruthenium (II) complexes. *J. Organomet. Chem.* 745, 64-70 (2013).
- 738 75. Kostova I, Kostova R, Momekov G, Trendafilova N, Karaivanova M. Antineoplastic activity of new lanthanide (cerium, lanthanum and neodymium) complex compounds. *J. Trace Elem. Med. Biol.* 18(3), 219-226 (2005).
- 741 76. Leon IE, Di Virgilio AL, Porro V *et al.* Antitumor properties of a vanadyl (IV) complex
 742 with the flavonoid chrysin [VO (chrysin) 2 EtOH] 2 in a human osteosarcoma model: the
 743 role of oxidative stress and apoptosis. *Dalton Trans.* 42(33), 11868-11880 (2013).
- 744 77. Chen Y-H, Yang Z-S, Wen C-C *et al.* Evaluation of the structure–activity relationship of
 745 flavonoids as antioxidants and toxicants of zebrafish larvae. *Food Chem.* 134(2), 717-724
 746 (2012).
- 747 78. Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. *Free Radic. Biol. Med.* 20(7), 933-956 (1996).
- This review compares the anti-oxidant potential of a range of flavonoid structures giving a detailed idea about the impact of each functional group on the anti-oxidant activity
- 751 79. Pietta P-G. Flavonoids as antioxidants. J. Na.t Prod. 63(7), 1035-1042 (2000).
- Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. *Nature*. 222(5191), 385 (1969).
- Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. *Chem. Rev.* 107(5), 1387-1407 (2007).
- 756 82. Pil P. Cisplatin and related drugs. *Encyclopedia of Cancer.* 1, 391-410 (1997).
- Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. *Chem. Rev.* 103(3), 645-662 (2003).
- 760 84. Tan J, Zhu L, Wang B. From GC-rich DNA binding to the repression of survivin gene for quercetin nickel (II) complex: implications for cancer therapy. *Biometals*. 23(6), 1075-1084 (2010).

- 763 85. Kaizer J, Baráth G, Pap J, Speier G, Giorgi M, Réglier M. Manganese and iron 764 flavonolates as flavonol 2, 4-dioxygenase mimics. Chem. Commun. (48), 5235-5237 (2007).765 86. Sahu SC, Gray GC. Interactions of flavonoids, trace metals, and oxygen: nuclear DNA 766 damage and lipid peroxidation induced by myricetin. Cancer Lett. 70(1-2), 73-79 (1993). 767 768 87. León I, Cadavid-Vargas J, Tiscornia I et al. Oxidovanadium (IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon 769 adenocarcinoma model. J. Biol. Inorg. Chem. 20(7), 1175-1191 (2015). 770 771 88. Naruse T, Nishida Y, Ishiguro N. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells. Biomed. Pharmacother. 61(6), 338-772 773 346 (2007). 89. León IE, Díez P, Etcheverry SB, Fuentes M. Deciphering the effect of an oxovanadium 774 (IV) complex with the flavonoid chrysin (VOChrys) on intracellular cell signalling 775 776 pathways in an osteosarcoma cell line. Metallomics. 8(8), 739-749 (2016). 777 90. Yang F, Gong L, Jin H et al. Chrysin-organogermanium (IV) complex induced Colo205 cell apoptosis-associated mitochondrial function and anti-angiogenesis. Scanning. 37(4), 778 779 246-257 (2015). Janka V, Žatko D, Ladislav V, Pál P, Janka P, Gabriela M. Some ferrocenyl chalcones as 780 91. useful candidates for cancer treatment. In Vitro Cell. Dev. Biol. Anim. 51(9), 964-974 781 (2015). 782 783 784
- 785